一项关于美金刚治疗重度抑郁症的双盲、安慰剂对照研究。
A double-blind, placebo-controlled study of memantine in the treatment of major depression.
作者信息
Zarate Carlos A, Singh Jaskaran B, Quiroz Jorge A, De Jesus Georgette, Denicoff Kirk K, Luckenbaugh David A, Manji Husseini K, Charney Dennis S
机构信息
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA.
出版信息
Am J Psychiatry. 2006 Jan;163(1):153-5. doi: 10.1176/appi.ajp.163.1.153.
OBJECTIVE
This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans.
METHOD
In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).
RESULTS
The linear mixed models for total MADRS scores showed no treatment effect.
CONCLUSIONS
In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.
目的
本研究旨在评估美金刚（一种选择性N-甲基-D-天冬氨酸（NMDA）受体拮抗剂）对人类可能的抗抑郁作用。
方法
在一项双盲、安慰剂对照研究中，32名重度抑郁症患者被随机分配接受美金刚（5-20毫克/天）（N=16）或安慰剂（N=16）治疗8周。主要疗效通过蒙哥马利-阿斯伯格抑郁评定量表（MADRS）的表现进行评估。
结果
MADRS总分的线性混合模型显示无治疗效果。
结论
在一项为期8周的试验中，剂量为5-20毫克/天的低至中等亲和力NMDA拮抗剂美金刚对重度抑郁症无效。
Zotero 插件